Inhibition of IL-4Rα reduces CCL26 in bronchial epithelial cells from COPD patients
Background Anti-interleukin (IL)-4Rα monoclonal antibodies (mAb) improve lung function and decreasethe number of exacerbations in patients with COPD type (T) 2 inflammation. However, the involvement ofearly innate immune responses underlying these treatment effects is not well known. We sought tounderstand the effect and mechanisms of IL-4Rα mAb treatment on bronchial epithelial cells (BECs) fromCBackgroundAnti-IL-4Rα monoclonal antibodies (mAb) improve lung function and decrease the number of exacerbations in patients with COPD type (T) 2 inflammation. However, the involvement of early innate immune responses underlying these treatment effects is not well known. We sought to understand the effect and mechanisms of IL-4Rα mAb treatment on bronchial epithelial cells from COPD patients under
